AdventHealth Orlando joins as newest trial site in pivotal Phase III trial

  Tariq Awan, DO, a double-certified family and sports medicine physician with a special focus in sports medicine enters as GID BIO’s newest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis. He has served as team physician for the […]

Wake Forest Medical School added as newest site in pivotal Phase III trial

Neil Sparks, DO, MS, a North Carolina physician specializing in the comprehensive primary and musculoskeletal care of children, adults and families, is the newest principal investigator in GID BIO’s pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis.Dr. Sparks leads a team of three, […]

UC Davis joins as trial site in pivotal Phase III trial

Charles De Mesa, DO, MPH, a Northern California practicing specialist in anesthesiology and pain medicine, physical medicine and rehabilitation and musculoskeletal pain medicine is GID Bio’s newest principal investigator in a pivotal Phase III trial evaluating cellular therapy for the treatment of pain and function as a result of knee osteoarthritis.  Dr. De Mesa leads a […]

OrthoCarolina joins as trial site in pivotal Phase III trial

OrthoCarolina, GID BIO’s newest Phase III trial site, is led by Dr. Claude T. Moorman III as principal investigator. Dr. Moorman is a sports medicine surgeon at OrthoCarolina’s Sports Medicine Center; the president of Atrium Health’s Musculoskeletal Institute; and Chair of Atrium Health’s Department of Orthopaedic Surgery. He has experience treating NFL, collegiate and high […]

<i>San Antonio Business Journal</i> features GID BIO and pivotal/Phase III trial principal investigator, Dr. Jaime Garza: “On the forefront of new cell therapy research, an Alamo City surgeon has a key role in moving new medical technology to market”

GID BIO completed a pivotal Phase IIb clinical trial with an FDA-compliant study design using autologous stromal cells in the treatment of knee osteoarthritis (OA), successfully meeting endpoints and two-year safety results… Read more via ORTHOWORLD: https://www.orthoworld.com/index.php/publications/orthoflash/gid-bio-completes-trial-of-stromal-cells-to-treat-knee-oa

New Jersey Regenerative Institute begins enrolling patients for GID BIO’s pivotal/Phase III clinical trial testing cellular therapy for knee osteoarthritis

Gerry Malanga, M.D., recent president of Interventional Orthobiologics Foundation, is the second principal investigator in our FDA-compliant pivotal/Phase III clinical trial for knee osteoarthritis. His practice, New Jersey Regenerative Institute, a center to treat sports and orthopedic injuries in the Northeast, begins patient enrollment along with Tulane University School of Medicine and Texas Center for […]